Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY736 multiple-dose study in moderate to severe primary Sjogren's syndrome
jRCT2080223583Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of ianalumab in Sjögren's syndrome (SS) (4 arms), sponsored by Novartis. Started Jul 2017; status: completed.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on jRCT2080223583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223583.